Tscan therapeutics to participate in the 13th annual wedbush pacgrow healthcare conference

Waltham, mass., aug. 03, 2022 (globe newswire) -- tscan therapeutics, inc. (nasdaq: tcrx), a clinical-stage biopharmaceutical company focused on the development of t cell receptor (tcr) engineered t cell therapies (tcr-t) for the treatment of patients with cancer, today announced that david p. southwell, president and chief executive officer, will participate in a virtual panel discussion titled “a view to a kill(er cell)” at the 13th annual wedbush pacgrow healthcare conference on wednesday, august 10, 2022 at 1:10 p.m. et.
TCRX Ratings Summary
TCRX Quant Ranking